Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | TAK-981 |
Trade Name | |
Synonyms | TAK981|TAK 981 |
Drug Descriptions |
TAK-981 is a small molecule inhibitor of SUMO, which may lead to activation of anti-tumor immune response (Cancer Res 2019;79(13 Suppl):Abstract nr 3252). |
DrugClasses | |
CAS Registry Number | 1858276-04-6 |
NCIT ID | C156270 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Avelumab + TAK-981 | Avelumab TAK-981 | 0 | 1 |
Cetuximab + TAK-981 | Cetuximab TAK-981 | 0 | 1 |
Daratumumab and hyaluronidase-fihj + TAK-981 | Daratumumab and hyaluronidase-fihj TAK-981 | 0 | 1 |
Mezagitamab + TAK-981 | Mezagitamab TAK-981 | 0 | 1 |
Pembrolizumab + TAK-981 | Pembrolizumab TAK-981 | 0 | 1 |
Rituximab + TAK-981 | Rituximab TAK-981 | 0 | 1 |
TAK-981 | TAK-981 | 0 | 2 |